Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The global market for HA viscosupplementation will exhibit moderate growth through 2027. While premium-priced 1-injection products will continue to become more popular over the forecast period, 3- and 5-injection products will continue to be preferred in some countries due to differences in product access, cost, and reimbursement.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for the US, Europe, Asia Pacific, and Brazil across a 10-year period.
The continuing introduction of 1-injection products and expanded indications in the HA viscosupplementation market will drive market growth.
How will the introduction of new products with more clinical data supporting the efficacy of HA treatment help offset the negative recommendation against HA injections by the AAOS in the US?
How fast are different geographies moving toward shorter treatment regimens, and how will the adoption of 1-injection products impact the market in the upcoming years?
How quickly will the nonknee market segment expand in the US following the anticipated approval of treatment for this indication?
Reimbursement for HA injections is facing greater scrutiny in Europe.
Which countries have limited or a complete lack of reimbursement for these products?
In France, what reimbursement changes have occurred and how will it impact the market?
What strategies can companies use to promote their products when reimbursement is lacking?
In the Asia Pacific region, domestic manufacturers have gained market share.
What are the factors influencing HA viscosupplementation market shares?
How are domestic manufacturers' product offerings evolving?
How will government initiatives, such as China's two-invoice policy, affect the market?
In which countries do domestic companies hold particularly high market shares and why?
Already a Client? Log in to access this report.
Diwakar Bahuguna is a research associate within the Orthopedics Medtech Insights team at Decision Resources Group. Diwakar holds a Bachelor's degree in Pharmacy from the Delhi Institute of Pharmaceutical Sciences and Research and an MBA in Pharmaceutical Management from the National Institute of Pharmaceutical Education and Research, Mohali.